ClinicalTrials.gg
CompletedNCT00729690Updated Dec 19, 2012Results posted

Effect of Oral Pregabalin on Spinal Neurotransmitters in Patients Undergoing Knee Replacement

A Phase 3 interventional study of Pregabalin and Pregabalin in PAIN, sponsored by Asokumar Buvanendran. Completed at 1 site in United States. Open to participants aged 55 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-12-19.

Sponsored by Asokumar Buvanendran · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
55 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies testing pregabalin in Pain — 4 open to participants now, 4 under way, none of them phase 3. Pregabalin · Pain.

Enrollment
35th of 55
48 · median 64
Started
2008
with 6 others
Phase 3
15 of 55
none open now
Registered
11th of 55
by date
Lead sponsor
1 of 55
Asokumar Buvanendran

Among the 55 studies testing pregabalin in Pain, this one is the 35th largest by enrollment, is one of 7 that started in 2008, is one of 15 in phase 3, and was the 11th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

4 of the 55 studies testing pregabalin in Pain are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 55 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing pregabalin in Pain, or all of them as a file.
02

Study summary

This study involves research. Pregabalin is a Food and Drug Administration (FDA) medication approved in the United States for the treatment of nerve pain related to diabetes and post-herpetic neuralgia "shingles", and for seizures in adults. The purpose of this research is to study the effect of oral Pregabalin on spinal neurotransmitters in subjects undergoing Total Knee Replacement Surgery (TKA). TKA is associated with considerable postoperative pain which if unrelieved may result in prolonged hospital stay, inability to participate in rehabilitation programs, poor outcomes, and greater use of health-care resources. This study examines the effect of pregabalin administered for TKA on pain-related neurotransmitter concentrations.

Read the detailed description

Gabapentin and the related more potent compound pregabalin have been shown to reduce postoperative pain in animal models (1). Pregabalin given before and after surgery reduced opioid use following spinal fusion surgery (2). Studies have identified the alpha 2 delta auxiliary subunit of voltage-gated calcium channels as the molecular target of pregabalin (and gabapentin), although the specific spinal site of action (presynaptic, postsynaptic) is not known.

Total knee arthroplasty (TKA) has proved to be a successful surgical treatment of knee joints affected by osteoarthritis. Currently in the United States, more than 400,000 TKAs are performed every year with reported success rates ranging from 85% to 90% (American Academy). In an aging population, the number of annual TKA procedures is expected to reach 3.48 million by the year 2030 (3).

TKA is associated with considerable postoperative pain which if unrelieved may result in prolonged hospital stay, inability to participate in rehabilitation programs, poor outcomes, and greater use of health-care resources. Perioperative pregabalin improves postoperative outcomes after TKA (4). This study examines the effect of pregabalin administered perioperatively for TKA on pain-related neurotransmitter concentrations, intrathecal analgesic consumption and range of motion (ROM). Pregabalin effects on neurotransmitter concentrations may identify pathways by which α2δ binding by pregabalin reduces postoperative pain.

Objectives:

Primary Endpoint: Measure effect of pregabalin on spinal neurotransmitters after TKA Secondary Endpoint: Correlate changes in spinal neurotransmitters with pregabalin to improvements in patient outcomes after TKA (e.g. ROM).

Other Endpoints: Suggest spinal anatomical sites of action of oral pregabalin as relates to neurotransmitter modulation and pain.

Methods:

Patient selection After approval of the Institutional Review Board of Rush University Medical Center, Chicago, Illinois, USA, 48 patients scheduled to undergo elective primary TKA by a single orthopedic surgeon will be contacted and assessed for study eligibility with a screening medical history.

A study consent form will be sent to patients who agreed to participate in the clinical study. After obtaining consent, the patient will be allocated a study number and the study drug dispensed to each participant. Using a random number table, patients will be allocated to one of three groups, without stratification by demographic characteristics:

Group 1 (n=16, multi-dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery and then repeat 150 mg doses at 12 and 24 hours after initial dose.

Group 2 (n=16, single dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.

Group 3 (n=16, placebo): patients receive matching placebo at the same 3 time points as Groups 1 and 2.

The 12 hour dosing interval was based on our pharmacokinetic study showing that after a 300 mg oral pregabalin dose, cerebrospinal fluid (CSF) pregabalin concentration reaches its peak at 8 h or later (5). Study drug administration on the day of surgery was timed to precede surgical incision by 60 +/- 30 minutes.

The physicians and nurses managing the patient during surgery and in the recovery room, the personnel involved with postoperative pain assessment and management of the intrathecal infusion, and the study patients will be blinded to group assignments. Treatment assignment codes will not be available to the investigators until all patients completed the study. A global pain score using the visual analogue scale (VAS) with 0 corresponding to "no pain" and 10 to "the worst imaginable pain" for the patient will be obtained before surgery. In the operating room, patients will be sedated with midazolam (0.05 mg/kg titrated to effect) and an intrathecal catheter placed in the sitting position, at the L3-4 or L4-5 vertebral level to deliver spinal anesthesia with bupivacaine 0.5%, (7.5 mg) and fentanyl 25mcg. Subjects will be maintained at normothermia in the operating room. A sensory analgesic level of T10 will be obtained prior to commencement of surgery. At completion of surgery an intrathecal infusion of fentanyl 0.5 mcg/ml and bupivacaine 0.1 mg/ml will be initiated using a continuous basal infusion with superimposed patient controlled intrathecal analgesia (PCIA) bolus doses. Initial infusion rates will be 4 ml/h basal intrathecal infusion plus PCIA of 1 ml q 12 min with a 4-hour lockout of 40 ml. The patients will be instructed prior to surgery to use PCIA mode at their discretion to maintain the VAS pain score \<4, following a previously applied protocol (6). A standardized surgical technique will be used in all subjects.

The intrathecal catheter will be left in place for 32 h postoperatively to provide analgesia, and lumbar CSF (0.5 ml) will be withdrawn (0.5 mL) at 2, 4, 8, 12, 24, and 32 h after the initial oral dose. CSF will be frozen at -80 Centigrade (C) for subsequent assay of neurotransmitter levels. Even though CSF pregabalin does not reach its peak concentration until at least 8 h after an oral dose, earlier time points are important because:

  1. Even at 2 h post-dose the CSF pregabalin concentration is already 29% of peak value, and may cause changes in neurotransmitter levels, compared to placebo.
  2. CSF inflammatory mediators, such as Interleukin-6 (IL-6), increase as early as 3 h after start of surgery after total hip arthroplasty (7), and so it can be expected that neurotransmitter levels will also show early changes due to the TKA surgery alone. Any characterization of pregabalin effects on neurotransmitters after surgery needs to also measure these early changes in neurotransmitter levels, since later time points (e.g. 24 h) are not independent of events occurring earlier.

Adverse Events:

Any adverse events will be noted and reported.

03

Conditions studied

  • PAIN

Browse trials for

Keywords

  • Pregabalin
  • CSF
  • Neurotransmitter
04

Who can participate

Ages eligible
55 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of osteoarthritis
  • Subjects who can understand and communicate in English

Exclusion criteria

Exclusion Criteria:

  • Younger than 55 years or older than 75 years.
  • physical status IV
  • Prior use of pregabalin or gabapentin will not be an exclusionary criterion; however patients will have been withdrawn from these medications at least 14 days before surgery
  • Patients who are currently enrolled in another study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    1 Multi-Dose Pregabalin

    Group 1 (n=16, multi-dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery and then repeat 150 mg doses at 12 and 24 hours after initial dose.

    Drug: Pregabalin

  • Experimental
    2 single-dose pregabalin

    Group 2 (n=16, single dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.

    Drug: Pregabalin

  • Placebo comparator
    3 Placebo

    Group 3 (n=16, placebo): patients receive matching placebo at the same 3 time points as Groups 1 and 2.

    Drug: Placebo

Interventions

  • Group 1 (n=16, multi-dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery and then repeat 150 mg doses at 12 and 24 hours after initial dose. Group 2 (n=16, single dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose. Group 3 (n=16, placebo): patients receive matching placebo at the same 3 time points as Groups 1 and 2.

    Also known as: Lyrica

  • Group 2 (n=16, single dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.

    Also known as: Lyrica

  • DrugPlacebo

    Group 3 (n=16, placebo): patients receive matching placebo at the same 3 time points as Groups 1 and 2.

    Also known as: Lyrica

06

What researchers measure

Primary outcomes

  1. NRS Pain Score AUC (NRS*hr) - 1st 24 Hours

    Numerical Response scale NRS(0-10) Pain scores were collected every 4 hours after the initial dose and the Area Under the Curve (AUC) calculated. Calculated for the 1st 24 hours after initial dose (0-24hr). AUC measured in NRS pain score points per hour (NRS\*hr). Larger AUC values indicate higher levels of reported pain.

    Time frame: 24 hours

  2. NRS Pain Score AUC (NRS*hr) - 1st 12 Hours

    Numerical Response scale NRS(0-10) Pain scores were collected every 4 hours after the initial dose and the Area Under the Curve (AUC) calculated. Calculated for the 1st 12 hours after initial dose (0-12hr). AUC measured in NRS pain score points per hour (NRS\*hr). Larger AUC values indicate higher levels of reported pain.

    Time frame: 12 hours Post dose

Secondary outcomes

  1. Active Knee Flexion

    The degree of active knee flexion (ROM) tolerated by the patient will be assessed at days 1 and 2 post-surgery. Active flexion is the unassisted moment of the joint by the subject. On postoperative (PostOp) day 2

    Time frame: PostOp day 2

  2. Passive Knee Flexion

    Passive flexion is the moment of the joint with the assistance of a clinician (The clinician or therapist physically hold and moves the knee through it's range of motion).

    Time frame: PostOp day 2

07

Results

Posted Dec 19, 2012

Participant flow

Forty-eight patients scheduled to undergo elective primary Total Knee Replacement (TKR) for osteoarthritis by 2 orthopedic surgeons were recruited at the Rush University Medical Center (Chicago, Illinois).

Participant flow — Overall Study
Milestone1 Multi-Dose Pregabalin2 Single-dose Pregabalin3 Placebo
Started161616
Completed161414
Not completed022
Withdrew: It catheter malfunction022

Outcome measures

PrimaryNRS Pain Score AUC (NRS*hr) - 1st 24 Hours

Numerical Response scale NRS(0-10) Pain scores were collected every 4 hours after the initial dose and the Area Under the Curve (AUC) calculated. Calculated for the 1st 24 hours after initial dose (0-24hr). AUC measured in NRS pain score points per hour (NRS\*hr). Larger AUC values indicate higher levels of reported pain.

Time frame:
24 hours
Reported as:
Mean · Area (NRS*hr)
NRS Pain Score AUC (NRS*hr) - 1st 24 Hours
Area (NRS*hr)1 Multi-Dose Pregabalin2 Single-dose Pregabalin3 Placebo
NRS Pain Score AUC (NRS*hr) - 1st 24 Hours70.4 ± 34.459.6 ± 31.173.4 ± 34.6
Statistical analysis
  • 1 Multi-Dose Pregabalin vs 2 Single-dose Pregabalin vs 3 Placebo · ANOVA · p = 0.4742
SecondaryActive Knee Flexion

The degree of active knee flexion (ROM) tolerated by the patient will be assessed at days 1 and 2 post-surgery. Active flexion is the unassisted moment of the joint by the subject. On postoperative (PostOp) day 2

Time frame:
PostOp day 2
Reported as:
Mean · Degrees
Active Knee Flexion
Degrees1 Multi-Dose Pregabalin2 Single-dose Pregabalin3 Placebo
Active Knee Flexion78.1 ± 10.680.5 ± 10.180.5 ± 7.0
Statistical analysis
  • 1 Multi-Dose Pregabalin vs 2 Single-dose Pregabalin vs 3 Placebo · ANOVA · p = 0.7596
PrimaryNRS Pain Score AUC (NRS*hr) - 1st 12 Hours

Numerical Response scale NRS(0-10) Pain scores were collected every 4 hours after the initial dose and the Area Under the Curve (AUC) calculated. Calculated for the 1st 12 hours after initial dose (0-12hr). AUC measured in NRS pain score points per hour (NRS\*hr). Larger AUC values indicate higher levels of reported pain.

Time frame:
12 hours Post dose
Reported as:
Mean · Area (NRS*hr)
NRS Pain Score AUC (NRS*hr) - 1st 12 Hours
Area (NRS*hr)1 Multi-Dose Pregabalin2 Single-dose Pregabalin3 Placebo
NRS Pain Score AUC (NRS*hr) - 1st 12 Hours30.1 ± 15.622.7 ± 16.927.7 ± 16.7
Statistical analysis
  • 1 Multi-Dose Pregabalin vs 2 Single-dose Pregabalin vs 3 Placebo · ANOVA · p = 0.4321
SecondaryPassive Knee Flexion

Passive flexion is the moment of the joint with the assistance of a clinician (The clinician or therapist physically hold and moves the knee through it's range of motion).

Time frame:
PostOp day 2
Reported as:
Mean · Degrees
Passive Knee Flexion
Degrees1 Multi-Dose Pregabalin2 Single-dose Pregabalin3 Placebo
Passive Knee Flexion86.5 ± 15.388.2 ± 9.4487.1 ± 10.6
Statistical analysis
  • 1 Multi-Dose Pregabalin vs 2 Single-dose Pregabalin vs 3 Placebo · ANOVA · p = 0.9361

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1 Multi-Dose Pregabalin—0/16 (0%)2/16 (12.5%)
2 Single-dose Pregabalin—0/16 (0%)3/16 (18.8%)
3 Placebo—0/16 (0%)7/16 (43.8%)
Most frequent other events
Most frequent other events
Event1 Multi-Dose Pregabalin2 Single-dose Pregabalin3 Placebo
PruritusSkin and subcutaneous tissue disorders2/163/167/16

Baseline characteristics

Age Continuous
Age Continuous(years)1 Multi-Dose Pregabalin2 Single-dose Pregabalin3 PlaceboTotal
Mean66.9 ± 6.464.8 ± 4.466.4 ± 4.566.1 ± 5.2
Sex: Female, Male
Sex: Female, Male(Participants)1 Multi-Dose Pregabalin2 Single-dose Pregabalin3 PlaceboTotal
Female1291334
Male47314
Region of Enrollment
Region of Enrollment(participants)1 Multi-Dose Pregabalin2 Single-dose Pregabalin3 PlaceboTotal
United States16161648
08

Study locations

1 site
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
09

References and documents

Publications

  • Buvanendran A, Kroin JS, Della Valle CJ, Moric M, Tuman KJ. Cerebrospinal fluid neurotransmitter changes during the perioperative period in patients undergoing total knee replacement: a randomized trial. Anesth Analg. 2012 Feb;114(2):434-41. doi: 10.1213/ANE.0b013e31823dc5fb. Epub 2011 Dec 9. PubMed 22156332 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Jun 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2012, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2008
First posted
Aug 7, 2008
Start
Aug 2008
Primary completionActual
Jun 2011
CompletionActual
Jul 2011
Results first posted
Dec 19, 2012
Last update
Dec 19, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00729690
Lead sponsor
Asokumar Buvanendran
Collaborators
Pfizer
Responsible party
Asokumar Buvanendran (Attending Physician, Rush University Medical Center) — Sponsor-investigator
First posted
Aug 7, 2008
Start date
Aug 2008
Primary completion
Jun 2011
Completion
Jul 2011
Results posted
Dec 19, 2012
Last update
Dec 19, 2012

Study contacts

Asokumar Buvanendran, MD
principal investigator · Rush University Medical Center
Jeffery S Kroin, PhD
principal investigator · Rush University Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion